Legend Biotech Corporation (LEGN) Stock Price & Analysis
Legend Biotech Corporation (LEGN) closed at USD 22.3 on Thursday, October 29, 2026, down 1.02% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 22.53; the Oct 29, 2026 session ranged USD 22.04–22.96 on volume of 2,372,094 shares. Market capitalization is $4.34B, with a 52-week range of USD 16.24–37.5 (NMS). Source: Nexqual, retrieved October 29, 2026 at 22:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LEGN.md
Key facts (LEGN)
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $480K; 4 not under a Rule 10b5-1 plan ($480K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (13 analysts), mean target USD 45.62 (range 24–68).
- Total return with dividends: 1Y -30.9% vs S&P 500 +14.4%; 5Y -57.5% vs S&P 500 +79.1%.
- Next earnings: 2026-11-10, EPS estimate USD 0.01, revenue estimate $360M. All companies reporting that day: https://nexqual.com/earnings/2026-11-10
- Dividend: LEGN paid no cash dividend in the last five years.
- Short interest: 16.91% of float (as of 2026-10-15), 6.1 days to cover.
Insider sales (SEC Form 4, open-market, last ~7 months) (LEGN)
0 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Sanders Corazon (corsee) D. | Director | 27,370 | $259K | 34.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-21 | Santos Carlos E | Chief Financial Officer | 5,430 | $50K | 27.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-30 | Casey Patrick John | Director | 6,000 | $89K | 11% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-25 | Huang Ying | Chief Executive Officer | 5,566 | $82K | 2.2% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (LEGN)
Consensus Buy (mean 2.00 on a 1–5 scale), 13 analysts; mean target USD 45.62 (low 24, high 68).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Barclays | Target lowered | Overweight | $74 → $68 |
| 2026-10-09 | JP Morgan | Target lowered | Neutral | $35 → $33 |
| 2026-10-08 | RBC Capital | Target lowered | Outperform | $58 → $56 |
| 2026-09-30 | HC Wainwright & Co. | Reiterated | Buy | $65 |
| 2026-09-11 | Barclays | Target lowered | Overweight | $78 → $74 |
| 2026-09-04 | HC Wainwright & Co. | Reiterated | Buy | $65 |
| 2026-08-12 | Morgan Stanley | Target raised | Overweight | $48 → $49 |
| 2026-08-12 | TD Cowen | Target lowered | Hold | $29 → $24 |
| 2026-08-12 | Oppenheimer | Downgrade | Outperform → Perform | $75 → $40 |
| 2026-08-12 | RBC Capital | Target lowered | Outperform | $59 → $58 |
| 2026-08-12 | Barclays | Target lowered | Overweight | $80 → $78 |
| 2026-07-28 | HC Wainwright & Co. | Reiterated | Buy | $65 |
Total return (dividends reinvested) (LEGN)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -30.9% | -57.5% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -30.9% | -15.7% |
| Volatility (annualized) | 72.3% | 53.2% |
| Max drawdown | -53.1% (Jun 2026→Sep 2026) | -78.0% (Jul 2023→Mar 2026) |
Dividends (LEGN)
LEGN paid no cash dividend in the last five years.
Short interest (LEGN)
13,904,472 shares sold short, 16.91% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 14,637,187 shares (-5.0%). Days to cover: 6.1 (short shares ÷ average daily volume).
LEGN earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.32 | $0.28 | Beat +14.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.16 | $0.19 | Miss −$0.35 | — |
| — | Quarter ended Sep 30, 2025 | −$0.22 | −$0.18 | Miss −22.2% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
LEGN recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 15, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 15, 2026 |
| Oct 13, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 13, 2026 |
| Sep 25, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 24, 2026 |
| Sep 24, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 24, 2026 |
| Sep 15, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 15, 2026 |
| Sep 14, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 14, 2026 |
| Aug 18, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 18, 2026 |
| Aug 11, 2026 | 6-K | Current report (foreign issuer) · period ended Jun 30, 2026 |
| Aug 6, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 6, 2026 |
| Aug 6, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 15.0% of shares, passive 5%+ holder (amended) |
| Jul 27, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 27, 2026 |
| Jul 15, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 15, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
LEGN suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Janssen Pharmaceuticals | “In connection with the Janssen Agreement, we entered into a Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc., dated as of October 6, 2025 (the "Raritan Supply Agreement") pursuant to which we will manufacture and supply cilta-cel to Janssen for clinical and commercial use worldwide (excluding Greater China) at the GMP manufacturing facility located at Raritan, New Jersey, which we and Jans…” |
| Supplier | Novartis Pharmaceuticals | “commercial supply agreements for BCMA CAR-T product with Novartis Pharmaceuticals Corporation (the "Novartis Supply Agreements"), pursuant to which Novartis agreed to manufacture cilta-cel for our clinical and commercial use to supplement our existing manufacturing capabilities.” |
| Partner | Novartis Pharma | “In addition, in November 2023, we entered into a License Agreement with Novartis Pharma AG (the "Novartis License” |
| Partner | Genscript | “We rely on Genscript to provide certain services.” |
| Partner | Nanjing Legend Biotech | “On June 27, 2025, Nanjing Legend Biotech Co., Ltd. entered into an Automation Project Agreement with Nanjing GenScript Biotech Co., Ltd., pursuant to which we and Genscript explored the development of an automated production line for Legend Biotech.” |
| Partner | Nanjing GenScript Biotech | “On June 27, 2025, Nanjing Legend Biotech Co., Ltd. entered into an Automation Project Agreement with Nanjing GenScript Biotech Co., Ltd., pursuant to which we and Genscript explored the development of an automated production line for Legend Biotech.” |
| Partner | Janssen Biotech | “•our ability to achieve specified milestones under our collaboration with Janssen Biotech, Inc., a Johnson & Johnson company ("Janssen") for cilta-cel or under other collaboration and license agreements we have entered into with other third parties;” |
| Partner | AquaPoint | “6.Through a family trust, Ms. Wang and her family hold 32.98% of AquaPoint L.P., whose general partner is Genscript Corporation, the largest holder of our largest shareholder, Genscript Biotech Corporation.” |
| Partner | Genscript Biotech | “6.Through a family trust, Ms. Wang and her family hold 32.98% of AquaPoint L.P., whose general partner is Genscript Corporation, the largest holder of our largest shareholder, Genscript Biotech Corporation.” |
| Partner | Nanjing Probio Biotech | “Nanjing Legend Biotech Co., Ltd. entered into a Collaboration and License Agreement dated as of February 25, 2024 with Probio, pursuant to which we and Probio agreed to collaborate to develop and commercialize products using certain of our and/or Probio's antibodies and their variants.” |
| Competitor | Johnson & Johnson (JNJ) | “•companies developing cell therapies targeting BCMA for the treatment of MM, including Arcellx, Inc./Kite, Autolus Therapeutics plc, Bristol-Myers Squibb, Co., Johnson & Johnson (the parent company of Janssen, our collaboration partner for cilta-cel, Caribou Biosciences, Inc., CARsgen Therapeutics Holdings Limited, Gracell Biotechnologies/AstraZeneca, IASO Biotechnology, Oricell Therapeutics, Poseida Therapeutics/…” |
Quoted from the company's 20-F filed Mar 10, 2026.
Companies that name LEGN in their SEC reports
| Relationship to LEGN | Company | Filing | Sentence |
|---|---|---|---|
| partner | Caribou Biosciences, Inc. (CRBU) | 10-K Mar 5, 2026 | “Autologous cell therapies directed at BCMA have been commercialized by Bristol-Myers Squibb Company (Abecma®) and Legend Biotech Corporation with their partner Johnson & Johnson (Carvykti®).” |
LEGN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.01 | $0.10 | -90.0% | $359.9M | 1 |
| Next quarter (ends Dec 2026) | $0.09 | $0.16 | -43.8% | $382.0M | 1 |
| Current fiscal year (ends Dec 2026) | $-0.01 | $0.30 | −$0.31 | $1.44B | 1 |
| Next fiscal year (ends Dec 2027) | $0.68 | $1.21 | -43.4% | $1.77B | 2 |
LEGN options: expected move
Options price a move of about ±18.5% (±$4.05) by Nov 20, 2026, which includes earnings on Nov 10, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 90.0% | ±18.5% |
| Dec 18, 2026 | 50 | 64.4% | ±19.6% |
| Jan 15, 2027 | 78 | 64.9% | ±24.5% |
| Feb 19, 2027 | 113 | 65.5% | ±29.6% |
| Mar 19, 2027 | 141 | 58.3% | ±29.3% |
| May 21, 2027 | 204 | 74.4% | ±44.6% |
30-day implied volatility 64.3% vs 52.2% realized over the last 30 trading days. Put/call ratio (volume) 0.05. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 22:22 UTC)
| Price | USD 22.3 |
|---|---|
| Change | ▼ 1.02% (down) |
| Previous Close | USD 22.53 |
| Open | USD 22.55 |
| Day Range | USD 22.04 – 22.96 |
| 52-Week Range | USD 16.24 – 37.5 |
| Volume | 2,372,094 shares |
| Market Cap | $4.34B |
| Exchange | NMS |
Technical Analysis (LEGN)
Nexqual's technical model rates LEGN "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 22:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.8 (neutral) |
| vs SMA50 | Above (USD 19.55) |
| MACD | 0.59 (positive) |
Analyst Ratings (LEGN)
Wall Street analysts rate LEGN "Buy" based on 13 analysts, with a mean price target of USD 45.62 (range USD 24–68), per Nexqual as of October 29, 2026 at 22:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 45.62 |
| High Target | USD 68 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 8 / 5 / 0 |
Earnings (LEGN)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD 0.01 |
| Revenue Estimate | $359.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.32 vs est 0.28 ▲ beat |
| 2025-12-31 | USD -0.16 vs est 0.19 ▼ miss |
| 2025-09-30 | USD -0.22 vs est -0.19 ▼ miss |
Source: Nexqual, October 29, 2026 at 22:22 UTC.
Financials & Fundamentals (LEGN)
| Total Revenue | $1.27B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +51.90% |
| Gross Margin | +56.57% |
| Operating Margin | +14.89% |
| Profit Margin | -7.20% |
| ROE | -8.08% |
| Debt / Equity | 0.23 |
| Current Ratio | 3.04 |
| Total Cash | $964.60M |
| Total Debt | $278.20M |
Source: Nexqual, October 29, 2026 at 22:22 UTC.
Financial Health Score (LEGN)
Nexqual rates Legend Biotech Corporation's overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 22:22 UTC.
| Growth | Strong — Revenue +64% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 15% (last 12 months) |
| Balance Sheet | Strong — $965M cash vs $278M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$89M (TTM) |
| Efficiency | Critical — ROE -8%, ROA -1.9% |
Ownership (LEGN)
| Insider Ownership | +1.90% |
|---|---|
| Institutional Ownership | +55.81% |
| Shares Outstanding | 194.49M |
| Float | 90.82M |
| Short % of Float | +16.91% |
Source: Nexqual, October 29, 2026 at 22:22 UTC.
Leadership (LEGN)
Legend Biotech Corporation is led by Ingrid Zhang, Chief Executive Officer, per Nexqual as of October 29, 2026 at 22:22 UTC.
| Chief Executive Officer | Ingrid Zhang |
|---|---|
| Chief Financial Officer | Carlos Santos Garcia |
| Senior Vice President of Global Manufacturing & Supply | Birk Vanderweeen |
| President of CARVYKTI Business Unit | Alan S. Bash |
Major Backers & Investors (LEGN)
Notable institutional backers of Legend Biotech Corporation include FMR, LLC, Fidelity, Deerfield Management Company, L.P, according to Nexqual as of October 29, 2026 at 22:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 15.01% |
| Fidelity | 6.73% |
| Deerfield Management Company, L.P | 4.2% |
| Montanova Capital LLC | 3.65% |
| HHLR Advisors, LTD | 3.09% |
| Westfield Capital Management Co LP | 2.29% |
| Goldman Sachs | 1.89% |
| Point72 Asset Management, L.P. | 1.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.44% |
Source: Nexqual, October 29, 2026 at 22:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt